These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37084469)

  • 1. Daily intranasal insulin at 40IU does not affect food intake and body composition: A placebo-controlled trial in older adults over a 24-week period with 24-weeks of follow-up.
    Becerra LA; Gavrieli A; Khan F; Novak P; Lioutas V; Ngo LH; Novak V; Mantzoros CS
    Clin Nutr; 2023 Jun; 42(6):825-834. PubMed ID: 37084469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial.
    Novak V; Mantzoros CS; Novak P; McGlinchey R; Dai W; Lioutas V; Buss S; Fortier CB; Khan F; Aponte Becerra L; Ngo LH
    J Neurol; 2022 Sep; 269(9):4817-4835. PubMed ID: 35482079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memory advancement by intranasal insulin in type 2 diabetes (MemAID) randomized controlled clinical trial: Design, methods and rationale.
    Galindo-Mendez B; Trevino JA; McGlinchey R; Fortier C; Lioutas V; Novak P; Mantzoros CS; Ngo L; Novak V
    Contemp Clin Trials; 2020 Feb; 89():105934. PubMed ID: 31923471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Intranasal Insulin in Type 2 Diabetes on Systemic Insulin: A Double-Blinded Placebo-Controlled Sub-Study of Memaid Trial.
    Aponte Becerra L; Galindo Mendez B; Khan F; Lioutas V; Novak P; Mantzoros CS; Ngo LH; Novak V
    Arch Diabetes Obes; 2022; 4(2):403-415. PubMed ID: 35903156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE).
    Rajeev SP; Roberts CA; Brown E; Sprung VS; Harrold JA; Halford JCG; Stancak A; Boyland EJ; Kemp GJ; Perry J; Howarth E; Jackson R; Wiemken A; Schwab R; Cuthbertson DJ; Wilding JPH
    Diabetes Obes Metab; 2023 Dec; 25(12):3621-3631. PubMed ID: 37667658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial.
    Heymsfield SB; Coleman LA; Miller R; Rooks DS; Laurent D; Petricoul O; Praestgaard J; Swan T; Wade T; Perry RG; Goodpaster BH; Roubenoff R
    JAMA Netw Open; 2021 Jan; 4(1):e2033457. PubMed ID: 33439265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk - Study rationale and design.
    Davidy T; Yore I; Cukierman-Yaffe T; Ravona-Springer R; Livny A; Lesman-Segev OH; Azuri Y; Carmichael O; Kapogiannis D; Zetterberg H; Lin H; Sano M; Beeri MS
    Mech Ageing Dev; 2023 Jul; 213():111825. PubMed ID: 37245533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes.
    Gibbons C; Blundell J; Tetens Hoff S; Dahl K; Bauer R; Baekdal T
    Diabetes Obes Metab; 2021 Feb; 23(2):581-588. PubMed ID: 33184979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design.
    Davidy T; Yore I; Cukierman-Yaffe T; Ravona-Springer R; Livny A; Lesman-Segev OH; Azuri Y; Carmichael O; Kapogiannis D; Zetterberg H; Lin H; Sano M; Beeri MS
    Mech Ageing Dev; 2024 Apr; 218():111898. PubMed ID: 38159613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol.
    Rajeev SP; Sprung VS; Roberts C; Harrold JA; Halford JC; Stancak A; Boyland EJ; Kemp GJ; Cuthbertson DJ; Wilding JP
    BMJ Open; 2017 Jan; 7(1):e013539. PubMed ID: 28132008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.
    Libman IM; Miller KM; DiMeglio LA; Bethin KE; Katz ML; Shah A; Simmons JH; Haller MJ; Raman S; Tamborlane WV; Coffey JK; Saenz AM; Beck RW; Nadeau KJ;
    JAMA; 2015 Dec; 314(21):2241-50. PubMed ID: 26624824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in Food and Nutrient Intake and Diet Quality on a Low-Fat Vegan Diet Are Associated with Changes in Body Weight, Body Composition, and Insulin Sensitivity in Overweight Adults: A Randomized Clinical Trial.
    Crosby L; Rembert E; Levin S; Green A; Ali Z; Jardine M; Nguyen M; Elliott P; Goldstein D; Freeman A; Bradshaw M; Holtz DN; Holubkov R; Barnard ND; Kahleova H
    J Acad Nutr Diet; 2022 Oct; 122(10):1922-1939.e0. PubMed ID: 35452873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes.
    Lee A; Morley JE
    Obes Res; 1998 Jan; 6(1):47-53. PubMed ID: 9526970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes.
    Schmidt S; Frandsen CS; Dejgaard TF; Vistisen D; Halldórsson T; Olsen SF; Jensen JB; Madsbad S; Andersen HU; Nørgaard K
    Diabetes Obes Metab; 2022 Feb; 24(2):212-220. PubMed ID: 34595827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study.
    Novak P; Pimentel Maldonado DA; Novak V
    PLoS One; 2019; 14(4):e0214364. PubMed ID: 31022213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
    Blundell J; Finlayson G; Axelsen M; Flint A; Gibbons C; Kvist T; Hjerpsted JB
    Diabetes Obes Metab; 2017 Sep; 19(9):1242-1251. PubMed ID: 28266779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A post hoc analysis of a randomized placebo-controlled 4.3-year trial.
    Out M; Miedema I; Jager-Wittenaar H; van der Schans C; Krijnen W; Lehert P; Stehouwer C; Kooy A
    Diabetes Obes Metab; 2018 Jan; 20(1):219-223. PubMed ID: 28681986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Olibra: a 12-week randomized controlled trial and a review of earlier studies.
    Rebello CJ; Martin CK; Johnson WD; O'Neil CE; Greenway FL
    J Diabetes Sci Technol; 2012 May; 6(3):695-708. PubMed ID: 22768902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.